Did Viemed Healthcare Inc (VMD.CA) beat earnings estimates last quarter?
Viemed Healthcare Inc (VMD.CA) missed EPS estimates and missed revenue estimates in the most recent quarter.
TSX:VMD • CA92663R1055
Past quarterly earnings results for Viemed Healthcare Inc (VMD.CA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2023 | 0.07 | 0.09 | -18.46% | 133.33% | 49.4M | 49.995M | -1.19% | 38.14% |
| Q2 2023 | 0.06 | 0.05 | 18.81% | 200.00% | 43.31M | 41.966M | 3.20% | 30.02% |
| Q1 2023 | 0.04 | 0.05 | -15.14% | - | 39.56M | 38.835M | 1.87% | 22.63% |
| Q4 2022 | 0.06 | 0.04 | 48.51% | -40.00% | 37.51M | 38.077M | -1.49% | 17.37% |
| Q3 2022 | 0.03 | 0.04 | -25.74% | -25.00% | 35.76M | 35.35M | 1.16% | 22.09% |
| Q2 2022 | 0.02 | 0.04 | -50.50% | -50.00% | 33.31M | 32.623M | 2.11% | 21.57% |
| Q1 2022 | 0.04 | 0.06 | -27.99% | - | 32.26M | 31.714M | 1.72% | 13.51% |
| Q4 2021 | 0.10 | 0.06 | 65.02% | -16.67% | 31.96M | 30.031M | 6.42% | 2.44% |
| Q3 2021 | 0.04 | 0.04 | -6.81% | -42.86% | 29.29M | 28.021M | 4.53% | -12.44% |
| Q2 2021 | 0.04 | 0.03 | 18.82% | -91.67% | 27.4M | 27.434M | -0.12% | -36.06% |
| Q1 2021 | 0.04 | 0.06 | -30.11% | -63.64% | 28.42M | 28.491M | -0.25% | 19.36% |
| Q4 2020 | 0.12 | 0.03 | 296.04% | - | 31.2M | 29.974M | 4.09% | - |
| Q3 2020 | 0.07 | 0.08 | -9.60% | - | 33.45M | 32.005M | 4.51% | - |
| Q2 2020 | 0.48 | 0.23 | 106.63% | - | 42.85M | 42.42M | 1.01% | - |
| Q1 2020 | 0.11 | 0.08 | 36.14% | - | 23.81M | 23.937M | -0.53% | - |
Notes
Viemed Healthcare Inc (VMD.CA) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, Viemed Healthcare Inc (VMD.CA) has beaten EPS estimates in 2 out of 4 releases.